HLA-C and hematologic disorder: APVO436 is a recombinant T-cell engaging humanized BiAB designed to redirect host T-cell cytotoxicity in an MHC-independent manner to CD123-expressing blast cells from patients with hematologic malignancies (Comeau et al., 2019; Uy et al., 2021b; Uy et al., 2017; Uckun et al., 2021) (Figure 2).